← All indications
Hypotension
Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.
Subtype terms (3)
More specific conditions that are subtypes of Hypotension in the MeSH hierarchy.
- Hypotension, Orthostatic
47 drugs (39 approved, 8 experimental)
- Post-Exercise Hypotension
- Shy-Drager Syndrome
9 drugs (7 approved, 2 experimental)
Drugs by status
Approved for this indication (7)
Phase 4 trials (54)
- ezetimibe
- ringer's lactate
- propofol
- nitroglycerin
- oxytocin
- Bismuth Subcitrate Potassium
- captopril
- ketamine
- tadalafil
- droxidopa
- enalapril
- fludrocortisone
- fosinopril
- isoflurane
- sevoflurane
- granisetron
- potassium
- albumin (Human)
- hydrocortisone
- Ocedurenone
- labetalol
- levocarnitine
- succinylcholine
- atorvastatin
- valsartan
- potassium chloride
- lidocaine
- epinephrine
- levobupivacaine
- bupivacaine
- +24 more
Phase 3 trials (17)
Phase 2 trials (27)
Phase 1 trials (8)
Other trials (28)
- tetracaine
- benzocaine
- carbon dioxide
- bradykinin
- glycopyrronium
- ramosetron
- etomidate
- chloroprocaine
- renasol
- mepivacaine
- metoclopramide
- methohexital sodium
- caffeine
- red blood cells
- remimazolam
- desflurane
- articaine
- terlipressin
- thiopental
- glucose
- l-cafedrine
- theodrenaline
- blood plasma
- procaine merethoxylline
- milrinone
- isoprenaline
- ciprofol
- gip (3-30)
Organizations
Organization Involved with Phase 4 Indications (61)
- Shire
- Fresenius
- Nimedical
- Grifols
- West-Ward Pharmaceutical
- University of Manitoba
- Ain Shams University
- Algemeen Ziekenhuis Maria Middelares
- Cairo University
- Cukurova University
- Harvard University
- Duke University
- Jeju National University
- Kyung Hee University
- Mahidol University
- Mongi Slim Hospital
- Northwell Health
- Seoul National University
- Sifa University
- Tunis University
- Universidad Industrial de Santander
- Ufuk University
- University of Nebraska
- University of Parma
- Utrecht University
- University of Brasilia
- West Virginia University
- University of Versailles
- University of Zagreb
- Yonsei University
- +31 more
Organization Involved with Phase 3 Indications (54)
- Chelsea Therapeutics
- Theravance
- Eli Lilly
- Sangart
- TSH Biopharm Corporation Limited
- Ataturk University
- University of London
- Institut National de la Santé Et de la Recherche Médicale, France
- Katholieke Universiteit Leuven
- KK Women's and Children's Hospital
- Loyola University
- New York University
- Ohio State University
- Queen's University, Belfast
- Semmelweis University
- University of Jordan
- University of Kansas
- University of South Florida
- University of Alberta
- University of Athens
- University of Virginia
- Mayo Clinic
- Peking University
- Royal College of Surgeons, Ireland
- Taipei Medical University
- Tel Aviv University
- Dalian Medical University
- University of British Columbia
- University of Copenhagen
- Vanderbilt University
- +24 more
Organization Involved with Phase 2 Indications (34)
- Roberts Pharmaceutical
- Santhera
- Juvantia Pharma Ltd
- Leading BioSciences, Inc
- MetaPhore Pharmaceuticals
- Meditor Pharmaceuticals Ltd.
- Orient Europharma Co., Ltd.
- Medinox, Inc.
- Kessler Foundation
- National Institutes of Health (NIH)
- National Center for Research Resources (NCRR)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Neurological Disorders and Stroke (NINDS)
- University of Arizona
- University of Pittsburgh
- American Heart Association
- Arizona State University
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Dartmouth University
- King Faisal University
- Mansoura University
- McGill University
- Stanford University
- University of Ottawa
- Virginia Commonwealth University
- Kantonsspital Münsterlingen
- Isfahan University
- University of Lyon
- Universidade do Extremo Sul Catarinens
- University of Sao Paulo
- +4 more
Organization Involved with Phase 1 Indications (26)
- GlaxoSmithKline
- Brown University
- Case Western Reserve University
- Emory University
- Indiana University
- New York Institute of Technology
- RTI International
- Tufts University
- University of Iowa
- University of New Mexico
- Wake Forest University
- Wayne State University
- Yale University
- University of Utah
- University of Queensland
- University of Texas at Houston
- PRACS
- University of Alabama, Birmingham
- National Institute of Public Health and the Environment, the Netherlands
- University of Western Ontario
- George Washington University
- Biohaven Pharmaceuticals Inc.
- Sungkyunkwan University
- National Institute of Child Health and Human Development (NICHD)
- Government of Netherlands
- The University of Texas, Dallas
Organization Involved with Other Experimental Indications (41)
- Clinical Evaluation Research Unit at Kingston General Hospital
- Dr. Soliman Fakeeh Hospital
- Rockefeller University
- Alexandria University
- Baylor University
- Benha University
- Canadian Critical Care Trials Group
- Cedars-Sinai Medical Center
- Inje University
- Nanjing Medical University
- Northwestern University
- Radboud University
- Rijnstate Hospital
- Siriraj Hospital
- Tulane University
- University Hospital, Mahdia
- University of Florida
- University of Rochester
- University of Toronto
- Fudan University
- Institute of Liver and Biliary Sciences, India
- Sprim Consulting
- University of Indonesia
- University of Strasbourg
- National University of Singapore
- Kassab Institute of Orthopedics
- University of Sherbrooke
- New Jeddah Clinic Hospital
- Canadian Institutes of Health Research (CIHR)
- Thrasher Research Fund
- +11 more